Why RAPT Therapeutics Stock Is Surging Today
RAPT Therapeutics Inc (NASDAQ: RAPT) shares are trading higher by 95% at $36.19 after the company reported topline results from its randomized placebo-controlled Phase 1b clinical trial of RPT193 as monotherapy in 31 patients with moderate-to-severe atopic dermatitis.